Customized treatment for coronary artery disease based on blood biomarkers
Use of Biomarker Risk Score to Optimize Therapy in Patients With Coronary Artery Disease: The Precision CAD Trial
NA · Emory University · NCT04755413
This study is testing if adjusting medications and lifestyle changes based on specific blood markers can help people with coronary artery disease feel better and avoid complications.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 450 (estimated) |
| Ages | 21 Years to 90 Years |
| Sex | All |
| Sponsor | Emory University (other) |
| Locations | 5 sites (Atlanta, Georgia and 4 other locations) |
| Trial ID | NCT04755413 on ClinicalTrials.gov |
What this trial studies
This study focuses on individuals with Coronary Artery Disease (CAD) who have elevated levels of specific blood biomarkers. Participants will be randomly assigned to either a treatment group, where their medications will be adjusted based on their biomarker levels along with lifestyle changes, or to a usual care group receiving standard treatment. The aim is to determine if this personalized approach can lower biomarker levels and reduce the risk of complications associated with CAD. The study will involve physical exams, blood tests, and questionnaires to assess outcomes.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 21-90 with stable coronary artery disease and elevated biomarker levels.
Not a fit: Patients with planned revascularization, severe heart failure symptoms, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective management of coronary artery disease and a reduction in serious complications.
How similar studies have performed: Other studies have shown promise in using biomarker-guided therapies for cardiovascular conditions, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals aged 21-90 years with stable CAD. * Patients with any amount of atherosclerosis via coronary angiogram or coronary computed tomography angiography (CCTA). * Patients undergoing revascularization therapy or recent acute coronary syndrome (ACS) will be eligible for recruitment and will be recruited at least 4 weeks after admission for an ACS or percutaneous intervention and 3 months after coronary bypass graft surgery. * Patients with CAC levels ≥ 400 Exclusion Criteria: * Planned revascularization, * New York Heart Association class III or IV heart failure symptoms, * LVEF \<40%, * eGFR\<45, * Pregnancy, congenital heart disease, severe symptomatic valvular heart disease, active malignancy and cardiac transplant.
Where this trial is running
Atlanta, Georgia and 4 other locations
- Emory Johns Creek Hospiatl — Atlanta, Georgia, United States (RECRUITING)
- Emory University Hospital Midtown — Atlanta, Georgia, United States (RECRUITING)
- Emory University Hospital — Atlanta, Georgia, United States (RECRUITING)
- The Emory Clinic — Atlanta, Georgia, United States (RECRUITING)
- Emory Saint Joseph's Hospital — Atlanta, Georgia, United States (RECRUITING)
Study contacts
- Principal investigator: Arshed Quyyumi, MD — Emory University
- Study coordinator: Joey Freshwater
- Email: joey.freshwater@emory.edu
- Phone: 404-712-6635
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Coronary Artery Disease, Biomarkers